natgillin/translations-raw huggingface dataset:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A method as claimed in Claim 14, wherein the solvent system of the inner coating preparation is aqueous. 
Postupak za koji se traži zaštita patenta u patentnom zahtjevu 11, pri čemu je sustav otapala unutarnjeg pripravka za oblaganje vodik.
A method of treating or ameliorating a syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject an effective amount of a compound of claim 1 or composition or medicament thereof in a combination therapy with one or more anti-inflammatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is selected from the group consisting of: rheumatoid arthritis, and psoriasis. The method of claim 1 wherein the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1 za uporabu u postupku liječenja ili ublažavanja sindroma, bolesti ili poremećaja, kod subjekta kojem je potrebno koji sadrži davanje subjektu učinkovite količine spoja prema zahtjevu 1 ili njegovog pripravka ili lijeka u kombiniranoj terapiji s jednim ili više protuupalnih sredstava, ili imunosupresiva, pri čemu je navedeni sindrom, bolest ili poremećaj odabran iz skupine koju čine, reumatoidni artritis i psorijaza.
ii) desorbing the adsorbed carbon dioxide from the resin by increasing the temperature and/or lowering the pressure in said bed, wherein the content of water in said bed of ion exchange resin during step i) amounts to more than 35 % of the total weight of ion exchange resin and water. 
desorbiranja apsorbiranog ugljičnog dioksida iz smole povećanjem temperature i/ili sniženjem tlaka u navedenom koritu. gdje sadržaj vode u navedenom koritu iono izmjenične smole u toku koraka i) iznosi više od 35% ukupne mase iono izmenične smole i vode.
In some embodiments, the detection step (b) comprises: (i) contacting the biological sample with a species-specific antibody which binds to the autoantibody against the target antigen, wherein the species-specific antibody is specific for the species from which the biological sample was obtained under conditions sufficient for specific binding of the species-specific antibody to the corresponding autoantibody present; and (ii) detecting any complex comprising the target antigen bound to the corresponding autoantibody, which is bound to the species-specific antibody. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se navedeni korak detekcije (b) sastoji u: (i) stavljanju u kontakt biološkog uzorka s protutijelom specifičnim za vrstu koje se veže na autoprotutijelo protiv ciljnog antigena, gdje je protutijelo specifično za vrstu iz koje je uzet biološki uzorak, u uvjetima dovoljnim za specifično vezanje protutijela specifičnog za vrstu na odgovarajuće prisutno autoprotutijelo; i (ii) detektiranju bilo kojeg kompleksa koji sadrži ciljni antigen vezan na odgovarajuće autoprotutijelo, vezano na protutijelo specifično za vrstu.
The title compound was obtained as a white solid (m= 111.76g) in a 76% yield. 
Spoj iz naslova se dobije u obliku bijele krutine (m = 111,76 g) s prinosom od 76 %.
A method of treating or ameliorating a coagulation factor deficiency in a mammalian subject comprising administering to the subject an effective amount of the conjugate of claim 7, wherein the coagulation factor is selected from FVII, FVIIa, FVIII, FIX, and FXI. 
HR P20190494 T1 prema zahtjevu 11, za uporabu u liječenju, ublažavanju ili prevenciji nedostatka faktora zgrušavanja kod sisavca, pri čemu je faktor zgrušavanja odabran iz skupine koja se sastoji od FVII, FVIIa, FVIII, FLX i FXI.
Use of an antibody or antigen-binding fragment thereof in the production of a medicament for the treatment of human VEGF-mediated endothelial cell proliferation and vascular permeability in a subject, the antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) and a variable light chain (VL), wherein the VH comprises rabbit CDRH1, CDRH2 and CDRH3 sequences of SEQ ID NO: 8, SEQ ID NO: 20 and SEQ ID NO: 32, respectively, and the VL comprises rabbit CDRL1, CDRL2, and CDRL3 sequences of SEQ ID NO: 43, SEQ ID NO: 55 and SEQ ID NO: 66, respectively, wherein the antibody or antigen-binding fragment thereof neutralizes human VEGF in the subject. 
Imunovezno sredstvo prema bilo kojem od zahtjeva 1 do 18, naznačeno time, da se primjenjuje u farmaceutski prihvatljivom doznom obliku za sljedeće puteve primjene: topikalno, intraokularno, intramuskularno, intraperitonealno, intracerebrospinalno, subkutano, intraartikularno, intrasinovijalno, intratekalno, oralno ili inhalacijski. Imunovezno sredstvo prema zahtjevu 4, naznačeno time, da VH obuhvaća sekvence CDRH1, CDRH2 i CDRH3 od SEQ ID NO:8, SEQ ID NO:20 odnosno SEQ ID NO:32, a VL obuhvaća sekvence CDRL1, CDRL2 i CDRL3 od SEQ ID NO:43, SEQ ID NO:55 odnosno SEQ ID NO:66.
utilizing the camera to generate an electronic image of at least a portion of the form; 
korištenja kamere za generiranje elektroničke slike barem dijela obrasca;
A process for validating a batch of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof for distribution comprising 
Postupak za validaciju šarže N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida ili njegove soli za distribuciju, naznačen time, da obuhvaća:
The oxalate salt of the compound of formula (II) 
Oksalatna sol spoja s formulom (II) [image]
The system of claim 8 further comprising a condenser (142). 
Sustav sukladno zahtjevu 8, koji dalje sadrži kondenzator (142).
p is 0, 1, or 2. In one embodiment, the disease is cancer or a proliferation disease. In a further embodiment, the disease is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreas cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, gliobastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemias, lymphomas, myelomas, and solid tumors. 
.Spoj prema bilo kojem od patentnih zahtjeva 1 do 18 ili farmaceutski pripravak prema patentnom zahtjevu 19 za uporabu u liječenju karcinoma ili proliferativne bolesti, poželjno gdje je bolest karcinom pluća, karcinom debelog crijeva, karcinom dojke, karcinom prostate, karcinom jetre, karcinom pankreasa, karcinom mozga, karcinom bubrega, karcinom jajnika, karcinom stomaka, karcinom kože, karcinom kosti, karcinom želuca, karcinom dojke, karcinom pankreasa, gliom, gliobastom, hepatostanični karcinom, papilarni bubrežni karcinom, karcinom skvamoznih stanica glave i vrata, leukemije, limfomi, mijelomi i solidni tumori ili gdje je karcinom multipli mijelom.
Figure 1 is a transverse sectional view of a portion of a shoe according to the invention, in a first embodiment; 
Slika 1 je prikaz poprečnog presjeka dijela cipele sukladno predmetnom izumu u prvom utjelovljenju;
A peptide as claimed in claim 5, formulated for injection. 
Peptid za koji se traži zaštita u patentnom zahtjevu 4, formuliran za ubrizgavanje.
The aqueous pharmaceutical suspension according to claim 3, wherein the xylitol, sorbitol or sorbitol solution, or maltitol solution is, by weight/volume (g/100 mL), 5% to 20%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola iznosi, težinskifvolumno (g/100 ml), 0 % do otprilike 20 %.
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is independently selected from-ORB, C1-3aliphatic, or halo. 
Cy1 je izborno dalje supstituiran sa jednim do tri nezavisna R6, pri čemu je svaki R6 nezavisno izabran od -ORB, C1-3 alifatika ili halo.
The compound of claim 14 wherein the compound of Formula VI is represented by Formule VIb: or an acceptable salt, thereof. 
Spoj u skladu s patentnim zahtjevom 14, naznačen time, da je spoj Formule VI predstavljen Formulom VIb:
RNA molecule consisting of or comprising SEQ ID NO: 117, SEQ ID NO: 118 or SEQ ID NO: 119 stimulating the innate immune response by addressing the receptors TLR-7, TLR-8, TLR-3, RIG-1 or MDA-5. 
RNA molekula koja se sastoji od ili sadrži SEQ ID NO: 117, SEQ ID NO: 118 ili SEQ ID NO: 119 naznačena time da je za stimuliranje urođenog imunog odgovora djelovanjem na receptore TLR-7, TLR-8, TLR-3, RIG-I ili MDA-5.
Also it was found that with a closure wall (i.e. the part 24 identified in Fig. 1 of WO-A-04/08317) thickness of 1-2mm less than 6% of the laser power was transmitted through the closure wall to reach the interior of the vial. 
Također je bilo nađeno, da je sa stijenkom zatvarača (to jest dio 24 koji je označen na slici 1 u WO-A-04/08317) debljine od 1-2 mm bilo preneseno manje od 6% snage lasera kroz stijenku zatvarača da bi moglo doći u unutrašnjost bočice.
administering to said patient, on days two, three and four, a second dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said second dose comprises from 40 to 60% of a minimum effective dose when administered alone. 
ako je navedeni pacijent podvrgnut visoko emetogenoj kemoterapiji, na dane dva, tri i četiri, druga doza deksametazona koja je neefikasna protiv mučnine i povraćanja kada je primjenjena pojedinačno, ali efikasna protiv mučnine i povraćanja kada je primjenjena u kombinaciji sa navedenim netupitantom, pri čemu navedena druga doza sadrži od 40 do 60% minimalne efikasne doze kada je primjenjena pojedinačno.
In another embodiment, the pharmaceutical composition in the article of manufacture comprises multiple doses of a pharmaceutical composition according to the present invention wherein such pharmaceutical composition is a single dose form that comprises Compound I and one or more of the other antidiabetic compounds specified herein. 
Upotreba farmaceutske kompozicije prema bilo kojem od patentnih zahtjeva 1-38 za proizvodnju lijeka koji sadrži kombinaciju spoja I i jednog ili više antidijabetičkih spojeva koji se razlikuju od spojeva I za liječenje dijabetesa tipa 1, pri čemu spoj I ima formulu 48.
is hydrogen or fluoro; and Ar is unsubstituted phenyl; or phenyl substituted with hydroxyC1-3 alkyl; or a pharmaceutically acceptable salt or a solvate thereof. 
R* je vodik ili fluoro; i Ar je nesupstituirani fenil; ili fenil supstituiran s hidroksiC, salkil; ili njegova farmaceutski prihvatljiva sol ili solvat.
In an advantageous further development of the threading device according to the invention, the threading device further comprises a plurality of toothed wheels adapted to transfer the movement of the rack to the arc-shaped element, In another development, a toothed belt is used to transfer the movement. 
Naprava za uvođenje užeta oko alke prema zahtjevu 3 ili 4, naznačena time da naprava za uvođenje užeta dodatno sadrži veći broj nazubljenih kotača (31, 32) koji su prilagođeni da prenose pomicanje letve (18; 118) na element u obliku luka.
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label item of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label item of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da formulacija matrice s produljenim otpuštanjem nakon što je bila skladištena pri 25 *C€ i 60% relativne vlažnosti zraka (RH) barem 1 mjesec sadrži količinu od oko jednog aktivnog agensa u % (težinski udio) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem koja odstupa ne više od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog agensa gledano u % (težinski udio) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem prema referentnoj formulaciji prije skladištenja.
is hydrogen, halogen, OH, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH2 units of said C1-C6 alkyl may be replaced with -O-; and 
je halogen, OH ili skupina C1-C6 alkil, pri čemu je navedena skupina C1-C6 alkil supstituirana s 0-6 halogena i pri čemu do dvije CH2 jedinice navedene skupine C1-C6 alkil koje nisu susjedne, mogu biti zamijenjene s-O-;
This procedure of SDS addition and then partial removal yields optimal conditions for close interaction of IL-2 and SDS molecules to form microaggregates of IL-2 and SDS as found in the PROLEUKIN™ product and, for a given IL-2/SDS ratio, it produces a different product from that obtained by simple mixing of SDS and IL-2. 
Ovaj postupak dodavanja SDS, a zatim djelomično odstranjivanje daje optimalne uvjete za blisku interakciju molekula IL-2 i SDS da se oblikuju mikroagregati od IL-2 i SDS kako je nađeno u proizvodu PROLEUKINTM i za dani omjer IL-2/SDS, on proizvodi različiti proizvod od onog koji se dobiva jednostavnim miješanjem SDS i IL-2.
The method of claim 17, wherein the first variable domain consists of the amino acid sequence of SEQ ID NO: 274. 
Polipeptid antitijela iz patentnog zahtjeva 1, gdje navedeni polipeptid antitijela sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 1355.
The combined organic extracts were washed 2x with IN HCl, 3x with 1M KOH, and 2x with brine prior to drying over Na2SO4. 
Spojeni organski ekstrakti su isprani 2x sa IN HCI, 3x sa IM KOH i 2x sa fiziološkom otopinom prije sušenja preko Na,SO,.
A compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a viral disease in a subject, wherein the viral disease is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus. Embodiment 43 
Spoj prema bilo kojem zahtjevu od 1 do 7 ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju virusnog oboljenja kod ispitanika, naznačen time, što je virusno oboljenje odabrano iz skupine koja se sastoji od ljudskog papilomavorusa, HIV-a, virusa hepatitisa B, virusa hepatitisa C, virusa boginja, virusa kravljih boginja, HR P20181871 T1 adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije, virusa mačje leukemije i virusa mačje imunodeficijencije.
In some embodiments, A is O. In some embodiments, R1 and R3 are H and R2 is selected from the group consisting of -carbocyclylR13, -heterocyclylR13, -arylR13 and -heteroarylR13. 
Spoj prema zahtjevu 1, naznačen time da R' i R* su H i R? je odabran iz skupine koja sadrži -karbociklilR'", - heterociklilR!", -arilR'", i -heteroarilR!".
Process according to claim 11, where said composition is found in the form of granules for oral solution, characterised in that it comprises the following steps: 
Postupak u skladu s patentnim zahtjevom 10, gdje navedeni pripravak dolazi u obliku granula za oralnu otopinu, naznačen time što se sastoji u sljedećim koracima:
According to one embodiment of the invention, it has proved to be particularly economical that the solid wood boards are waste boards which are produced in the conventional manufacturing process of veneers. 
U skladu s jednim ostvarenjem ovog izuma, pokazuje se daje naročito ekonomično da su ploče od punog drva otpadne ploče koje se dobivaju u konvencionalnom proizvodnom postupku furnira.
A pharmaceutically acceptable liquid composition comprising carbidopa, 4% to 20% by weight levodopa; and arginine, wherein said composition has a pH of 9.1 to 9.8 at 25°C, and the molar ratio of levodopa plus carbidopa to the arginine is 1:1.8 to 1:3.5. The pharmaceutically acceptable liquid composition of claim 1, comprising 4% to 12%, or 10% to 20%, by weight, levodopa. 
Farmaceutski prihvatljiv tekući sastav sadržeći 2,5% do 7% masenog udjela levodopa; do 2% masenog udjela karbidopa; 5% do 18% masenog udjela arginina; i 0,25% do 3% masenog udjela askorbinske kiseline ili farmaceutski prihvatljive soli iste, naznačeno time da spomenuti sastav ima pH vrijednost od 9,1 do 9,8 na 25", te je molarni omjer levodopa sa karbidopom u odnosu na arginin 1:1,8 do 1:3,5.
a cytotoxic agent, optionally a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme; 
citotoksičko sredstvo, opcijski kemoterapeutsko sredstvo, funkcionalni dio lijeka, antibiotik, radioaktivni izotop, i nukleolitički enzim; ili
exposing to humid air (relative humidity under 60 %) when the assay of water is below 4.1 % to achieve an assay of water not more than 5.0 % (Karl Fischer). 
- < izlaganje vlažnom zraku (relativna vlažnost ispod 60 %) pri čemu je esej vode ispod 4,1 % čime se postiže da esej vode nije viši od 5,0 % (određeno Karl Fischerovom metodom).
and/or, in the preparation of compound 5, the ratio of the volume of the solvent to the mole of compound 7 is in the range of 1.3-1.6 L/mol; 
i / ili u pripremi spoja 5, omjer volumena otapala prema molu spoja 7 je u rasponu od 1,3-1,6 L/mol;
measuring the quantity of compactin C in the isolated sample from d); determining whether or not the quantity of compactin C in e) is less than about 0.16% by weight; and purifying by crystallization the composition resulting from d) if the quantity of compactin C measured in e) is about 0.16% by weight or more until the quantity of compactin C is less than about 0.16% by weight, and synthesizing a pravastatin composition from the composition so purified; or, 
£) pročišćavanje kristalizacijom smjese iz d) ako je količina kompaktina određena u e) oko 0.16% težine ili više, sve dok količina kompaktina C ne bude manja od 0.16% težine, 1 sintezu smjese pravastatina iz tako pročišćene smjese; ili, h) ako je količina kompaktina C određena u e) manja od 0.16% težine, sintezu smjese pravastatina iz smjese iz koraka d).
Process according to claim 24, characterized in that the axis of rotation of the rotary machining tool is essentially perpendicular to the adhesion surface to be processed. 
Postupak u skladu s patentnim zahtjevom 23, naznačen time, što je os rotacije rotacijskog alatnog stroja uglavnom okomita na površinu koja se lijepi i koju se treba obraditi.
The body of the central leg of flat plate 8 has a central through groove 8b, which is engaged in sliding manner by the portion of supporting bracket 11 surrounding cylindrical pin 10, so that the C-shaped end of the central leg of flat plate 8 can reach and engage cylindrical pin 10 in freely rotating manner. 
Tijelo centralne nožice ravne ploče 8 ima srednji prorez 8b, koji je na klizni način zahvaćen dijelom potporne konzole 11 koja okružuje cilindrični štift 10, tako da C-oblikovani kraj centralne nožice ravne ploče 8 može dosegnuti i zahvatiti cilindrični štift 10 na slobodno rotirajući način.
The compound for use of claim 1, wherein the disease or disorder is lymphoma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak prostate.
is halogen, preferably fluorine or chlorine, is hydrogen and R3 is hydroxyl or 
R! je halogen, poželjno fluor ili klor, R- je vodik i R? je hidroksil ili 20
The antibody, or binding fragment thereof for use according to Claim 15 or the pharmaceutical composition for use according to Claim 15, wherein said chronic viral infection is selected from the group consisting of: HIV, HBV and HCV. 
Protutijelo ili njegov fragment za vezanje, za uporabu prema patentnom zahtjevu 14, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, naznačen/o time, da se kod kronične virusne infekcije radi o virusnoj infekciji odabranoj iz skupine koju čine HIV, HBV i HCV.
mixing the activated bacterial saccharide with a carrier protein; reacting the activated bacterial saccharide and the carrier protein with a reducing agent to form a conjugate; 
reakcija aktiviranog bakterijskog saharida sa spojnicom uz upotrebu reducensa kako bi se dobio kompleks bakterijski saharid-spojnica; d) reakcija kompleksa bakterijski saharid-spojnica s proteinskim nosačem kako bi se dobio konjugat;
which process comprises the steps of converting the compound of the Formula VII to a compound of the Formula IX: 
VII; gdje je R' zaštitna skupina labilne kiseline naznačen time, da navedeni postupak obuhvaća korake pretvorbe spoja sa formulom VII u spoj sa formulom IX:
The final mixture is compressed on a suitable tablet press to produce, for example, oblong shaped matrix tablets (ER tablets=extended release tablets). 
(5) tabletiranje granula iz koraka (3) ili konačne mješavine iz koraka (4) njezinim komprimiranjem u prikladnoj preši za tablete da bi se pripravile matrice tableta.
reacting a compound of the formula II A-(CH2)m-X II wherein A is as previously defined, m is 0, 1 or 2 and X is a leaving group, with a compound of the formula III wherein Z, n, R2, R3 and R4 are as previously defined; 
(a) reakcija spoja formule II A-(CH>)p=X II gdje A je kao prethodno definiran, m je 0, 1 ili 21 X je izlazeća skupina, sa spojem formule III
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired. 
Vodene otopine prikladne za oralnu uporabu se mogu pripremiti otapanjem aktivnog sastojka u vodi i dodavanjem prikladne boje, korigensa okusa, sredstva za stablizaciju i zgušnjavanje ako je to poželjno.
or a pharmaceutically acceptable acid addition salt. 
ili farmaceutski prihvatljiva kiselinska adicijska sol.
Ring A is optionally substituted with 1 or 2 substituents selected from: halogen, 
Prsten A je po izboru supstituiran s 1 ili 2 supstituenda izabrana iz skupine koju čine: halogen,
A host cell transformed with the vector according to claim 1 to 3. 
Stanica-domaćin, naznačena time što je transformirana vektorom u skladu s patentnim zahtjevom 1 do 3.
The process of claim 19, wherein the suitable Boc deprotecting agent is HCl or TFA and the suitable solvent is acetone or CH2Cl2. 
Postupak u skladu s patentnim zahtjevom 19, naznačen time, da je prikladno sredstvo za uklanjanje zaštite Boc HCI ili TFA, a pogodno otapalo je aceton ili CH,Cb.
Rate of application (g/ha) 
Stopa primjene (g/ha) Diklormid
The formulation of claim 5 for use of claim 1, wherein said compound is cycloastragenol. 
Formulacija u skladu s patentnim zahtjevom 5 za upotrebu u skladu s patentnim zahtjevom 1, naznačena time što je navedeni spoj cikloastragenol.
The residue was purified by chromatography, eluting with 0 to 2.5% (7:1 MeOH/concentrated aqueous NH4OH) in DCM. 
Talog je pročišćen kromatografijom, uz ispiranje sa O do 2.5 % (7:1 MeOH/koncentrirani vodeni NH4OH) u DCM-u.